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Abstract
The number of known pathologies involving deregulated Tau expression/metabolism is increasing. Indeed, in
addition to tauopathies, which comprise approximately 30 diseases characterized by neuronal aggregation of
hyperphosphorylated Tau in brain neurons, this protein has also been associated with various other pathologies
such as cancer, inclusion body myositis, and microdeletion/microduplication syndromes, suggesting its possible
function in peripheral tissues. In addition to Tau aggregation, Tau deregulation can occur at the expression and/or
splicing levels, as has been clearly demonstrated in some of these pathologies. Here, we aim to review current
knowledge regarding the regulation of human MAPT gene expression at the DNA and RNA levels to provide a
better understanding of its possible deregulation. Several aspects, including repeated motifs, CpG island/
methylation, and haplotypes at the DNA level, as well as the key regions involved in mRNA expression and stability
and the splicing patterns of different mRNA isoforms at the RNA level, will be discussed.
Keywords: Tau, Tauopathy, MAPT, Alzheimer’s disease, Repeat sequences, CpG islands, Tau haplotype, Tau
promoter, Tau splicing
Introduction
Tau proteins are expressed primarily in the brain and,
more precisely, in neurons. These proteins were discov-
ered in 1975 and identified as important mediators of
cerebral microtubule polymerization and stabilization [1]
(reviewed in [2, 3]). Since then, other roles for Tau
proteins have been demonstrated. Tau is involved in
axonal transport (reviewed in [4, 5]), synaptic plasti-
city/function (reviewed in [6, 7]) and nucleic acid
protection [8, 9], depending on its cellular localization
(cell body/axon, cytoplasmic membrane, or nucleus).
The functional importance of Tau is underscored by
the involvement of Tau deregulation in neurodegenera-
tive diseases. Aggregation of hyperphosphorylated Tau
proteins in degenerating neurons, which leads to the for-
mation of neurofibrillary tangles, occurs in a group of
pathologies termed tauopathies (reviewed in [3]). The re-
lationship between Tau proteins and pathophysiology is
supported by the identification of autosomal dominant
mutations in the Tau gene, MAPT, in various tauopa-
thies, such as frontotemporal dementia with parkinson-
ism linked to chromosome 17 (FTDP-17) (reviewed in
[10, 11]). Although certain tauopathies are clearly pure
neurodegenerative diseases, such as Alzheimer’s disease
(AD), progressive supranuclear palsy (PSP), corticobasal de-
generation (CBD), and FTDP-17, some are associated with
the development of other pathologies, such as arterioven-
ous malformation [12], brain tumors (such as ganglion cell
tumors) [13, 14], viral infection (such as subacute sclerosing
panencephalitis (SSPE) [15] and postencephalitic parkin-
sonism [16]), developmental abnormalities (verrucose dys-
plasia [17]), Down syndrome [18], myotonic dystrophy
(DM) [19], parkinsonism-dementia of Guam [16, 20], trau-
matic brain injury [21, 22], and Huntington’s disease [23].
Tau isoforms are translated from alternatively spliced
mRNA, and some or all of these isoforms aggregate, de-
pending on the pathology (reviewed in [3]). Deregulated
Tau expression and missplicing have been reported in
several pathologies. The direct involvement of a splicing
defect has been clearly demonstrated for FTDP-17 and DM
types 1 and 2 (reviewed in [24]). Some patients with amyo-
trophic lateral sclerosis (ALS) or frontotemporal lobar de-
mentia (FTLD) exhibit the nearly complete absence of Tau
protein in the cortex despite normal Tau mRNA expres-
sion. These latter two pathologies, ALS and FTLD, are
characterized by the presence of ubiquitin-positive aggre-
gates composed of TDP-43 (transactive response DNA
binding protein 43 kDa) [25–27], as reviewed in [28].
Furthermore, MAPT is a major candidate involved in
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pathology characterized by the microdeletion of a small
chromosomal region (from 650 to 1,608 kb) containing sev-
eral genes, including MAPT. The symptoms of 17q21.31
microdeletion syndrome include mental retardation, hypo-
tonia and characteristic facial features. Pathological pheno-
types have also been associated with microduplications or
microtriplications containing MAPT [29–32]. One of the
single-nucleotide polymorphisms (SNPs) within the MAPT
locus has been found to be associated with AD in patients
without ApoE e4 [33]. The MAPT locus is an important
genetic risk factor for Parkinson’s disease (PD) [33–35].
Taken together, these data demonstrate the complexity of
Tau expression in the brains of healthy individuals and pa-
tients with the above-mentioned diseases.
More recently, several reports have suggested that Tau
interferes with certain pathologies involving tissues other
than the brain. For example, Tau aggregation has been
reported in the muscles of patients suffering from inclu-
sion body myositis (IBM), an inflammatory muscle dis-
ease [36, 37]. Furthermore, Tau expression may have a
prognostic or predictive value in some cancers affecting
various tissues, such as breast [38, 39], prostate [40, 41],
ovary [42, 43], bladder [44], and stomach cancers [45].
Tau expression could be related to certain sub-types of
cancer; for example, it is increased in hormone-
dependent breast cancer [39, 46]. Such an increase in
Tau expression may result in resistance to microtubule-
targeting drugs [43, 47–56].
Despite the importance of the deregulation of Tau
expression/metabolism in many pathologies, the regu-
lation of the expression of the MAPT gene, which en-
codes Tau protein, has been the subject of few articles;
more articles have focused on the function of Tau pro-
tein or its roles in various pathologies. The most com-
monly studied aspects include MAPT haplotypes and
Tau RNA splicing because of their involvement in cer-
tain tauopathies (for examples, see reviews [57–61]).
Research regarding the epigenetic regulation of Tau ex-
pression is increasing. However, some aspects of Tau
gene expression, such as the possible existence of dif-
ferent promoters and the potential role of the repeated
motifs found in all MAPT sequences, have rarely been
studied, despite the availability of abundant data in
bioinformatics databases. The aim of this review is to
provide a global synthesis of knowledge regarding the
regulation of human MAPT gene expression at the
DNA and RNA levels by evaluating data from the lit-
erature and bioinformatics databases. Several aspects
will be discussed, including repeated motifs, CpG is-
land/methylation, and haplotypes at the DNA level as
well as the key regions involved in mRNA expression
and stability (i.e., the 5′ and 3′ untranslated regions
[UTRs]) and the splicing patterns of different mRNA
isoforms at the RNA level.
DNA regulatory elements involved in Tau
expression
The human MAPT gene is a long (134 kb) gene located
on chromosome 17q21. Its sequence is well conserved
among mammals, exhibiting 97 to 100 % homology
with primates. This observation is quite surprising
considering the specific human susceptibility to devel-
oping tauopathies.
Repeated sequences
Numerous repeated sequences are spread throughout
the human genome. These sequences can be classified
into two groups: transposons and satellites.
Transposon-type repeats
Transposon-type repeats can be classified into the fol-
lowing four categories: short interspersed nuclear ele-
ments (SINEs), long interspersed nuclear elements
(LINEs), DNA transposons, and transposable elements
with long terminal repeats (LTRs). All 4 categories of
this type of repeat are found in the MAPT gene. Gener-
ally, SINEs are the most numerous, and among them,
Alu sequences are the most frequent. Alu elements are
300-nucleotide (nt) sequences that occupy over 10 % of
the human genome. These sequences contribute to gen-
omic instability by eliciting gene mutations, altered gene
expression and transcript splicing or by generating a
new gene segment [62]. Among the 83 Alu sequences
identified in the MAPT gene using the TranspoGene
database [63], 56 are on the sense strand and 27 are on
the antisense strand. These sequences are located within
intronic sequences, independent of the considered iso-
form. Alu sequences have also been localized to the
MAPT promoter in a region upstream of the first exon
(E0) [64, 65]. In addition, other types of repeated se-
quences have been identified in the MAPT gene, some of
which are located in the promoter [64]. However, the
impact of these sequences on promoter activity is not
well understood.
Simple sequence repeats (SSRs)/microsatellites and
minisatellites
SSRs are short repeated sequences that are abundant
throughout eukaryote genomes, are localized to intergenic
or genic regions, and constitute an important class of gen-
etic markers. Depending on the length of the repeat, SSRs
can also be called microsatellites (1 to 13 bases per repeat)
or minisatellites (14 to 100 bases per repeat) [66]. The roles
of these microsatellites/minisatellites are varied and are not
all well understood. However, some effects of these mo-
tifs have begun to be reported. For example, dinucleo-
tide motifs have been identified as part of a general
enhancer feature (i.e., non-cell type-specific enhancers)
[67]. Furthermore, SSRs affect DNA structure, gene
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expression and genomic stability and can lead to a
toxic gain-of-function in an RNA or protein when the
number of repeats increases, as has been observed in a
growing number of neurodegenerative diseases. For ex-
ample, DM and Huntington’s disease involve an RNA
and protein, respectively, with a toxic gain of function
(reviewed in [68, 69]).
SSRs can be found throughout the MAPT gene using
the Tandem Repeats Finder program (TRF/UCSC) [70].
Interestingly, the first genetic marker identified as over-
represented in PSP patients was a dinucleotide repeat
(11xTG, named TG11) downstream of exon 9 ([71, 72],
reviewed in [60]). Some of these repeats are clearly dis-
tinguishable based on the following features: (i) their re-
peat length (4 sequences are longer than 20 nt, and the
longest sequence is 58 nt); (ii) their localization through-
out the gene (shorter sequences of less than 20 nt are lo-
cated before exon E4, whereas the longest sequence,
which is more than 20 nt long, is located after E4); (iii)
their proximity to alternative exons; and (iv) the repeat
lengths of certain imperfect repeats, such as those of the
dinucleotides TA or GT in intron 0 (TA356, GT187)
(Fig. 1). A 58-nt motif (SSR58) that is repeated twice is
located immediately upstream (precisely 10 nt) of the al-
ternatively spliced E10 [73, 74]. Interestingly, the copy
number of this long repeat seems to influence the spli-
cing pattern of this exon [73]. Although no functional
role has been demonstrated, notably, a dinucleotide GT
repeat (x22: GT22) has been identified immediately
downstream of E0 (precisely 362 nt from E0) in the
human gene, as first reported by Andreadis et al. [75].
Compared with the mouse sequence, half of this human
TG repeat corresponds with an insertion in a sequence
that is well-conserved (76 % homology) between human
and mouse E0. However, a similar 23-repeat TG se-
quence also exists in intron 0 of mouse MAPT, but it is
located 7301 nt downstream instead of 362 nt down-
stream of E0 in a non-homologous region of the human
gene. We also observed 4 different short regions con-
taining CATC or CCAT repeats located immediately
downstream (from 46 to 1200 nt) of the internal exon
E1A, between E1 and E2 in the only MAPT transcript
that is potentially subjected to nonsense-mediated decay
(NMD) (MAPT-011 ENST00000571311) (Fig. 1, Fig. 4b).
CpG islands and methylation
CpG islands
As determined by CpG Islands Track Settings (UCSC),
one long CpG island spans approximately 300 nt up-
stream to 3000 nt downstream of E0 in human MAPT
(the total [G + C] increases to 75 % around the tran-
scription start site, with as high as 10 % CpG dimers)
[76–78]. This CpG island (CpG300) is located in the
promoter region (Fig. 1, Fig. 2). Two additional but more
limited sequences are present, including one containing 27
CpGs (CpG27) that is located 13 kb upstream of E1 and an-
other containing 21 CpGs (CpG21) that is located immedi-
ately upstream of E4A (UCSC Genome Browser [79]). The
CpG21 island is situated at the beginning of the short tran-
script MAP-010/ENST00000576238 (Fig. 1, Fig. 4b). Thus,
we cannot ignore the possibility that this CpG island may
be involved in the transcriptional regulation of this minor
transcript (see section 3.1.3). However, no histone H3 lysine
4 trimethylation, another feature of promoter regions, was
found in this third CpG island (CpG21) using CpG Islands
Track Settings (UCSC genome browser) [76, 80]. In
addition to these three CpG islands, other CpG islands can
be identified using less restrictive conditions. For example,
one CpG island was identified in exon E9 (198 nt/266)
using MethPrimer (http://www.urogene.org/methprimer)
[75, 81]. This type of CpG island is a 3′ island as defined by
Gardiner-Garden and Frommer [76]; however, no methyla-
tion studies of this type of island have been reported. An-
other CpG island has been predicted in the coding region
of the last exon, E13, using the same MethPrimer tool [81].
DNA methylation
Effective DNA methylation has been identified in both
CpG300 and CpG27 islands; however, functional studies
have focused primarily on the CpG300 island located
around E0. In the brain, MAPT methylation varies accord-
ing to the area analyzed [82, 83]. Interestingly, DNA
Fig. 1 DNA satellite sequences and CpG islands in the MAPT gene. Only the repeats discussed in the text are indicated. The complete list can be
found on the UCSC site. White, non-coding regions; color, coding regions; gray, constitutive coding exons. Yellow, orange, pink, green, purple
and blue represent the alternative exons 2, 3, 4A, 6, 8 and 10, respectively
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hypomethylation has been observed in various patholo-
gies, such as PSP, AD and PD [82, 83]. These differences
have been observed in neuronal and non-neuronal cells in
cases of sporadic AD [83]. MAPT hypermethylation leads
to decreased Tau expression, suggesting that the hypome-
thylation observed in AD is associated with an increase in
Tau protein expression and thus could participate in ag-
gregation seeding and pathological propagation through
the brain via a prion-like mechanism [83]. Concerning PD,
hypermethylation in the cerebellum (the region spared in
PD) and hypomethylation in the putamen (the region with
the highest level of PD pathology) are consistent with re-
ports on AD, with a possible neuroprotective effect of DNA
hypermethylation by reducing MAPT expression. Further-
more, the neuroprotective effect of MAPT hypermethyla-
tion is somewhat illustrated by the fact that higher
methylation in Parkinson leukocytes is associated with late-
onset PD [82]. However, some contradictory results have
been reported, including no changes in methylation in AD,
PD and some cases of frontotemporal dementia (FTD) [84].
These differences might have resulted from the analysis
method used (microarray analysis/pyrosequencing) and/or
the brain region analyzed (hippocampus, frontal cortex/
cerebellum, parietal cortex and temporal cortex).
Haplotypes
Tau haplotypes and neurodegenerative disease
development
More than 120 nucleotide changes across the MAPT gene
have now been described, 60 % of which are primarily lo-
calized to two clusters in introns 9 and 10 [85]. An atyp-
ical pattern of linkage disequilibrium results in 2 major
haplotypes: H1 and H2. Among the genetic variations, the
H2 haplotype differs from H1 by the deletion of a 238 bp
sequence upstream of Tau exon 10 (reviewed in [60]). An-
other feature of the H2 haplotype is the inversion of a
900 kb sequence, most likely due to non-allelic homolo-
gous recombination between the long coding repeats
(LCRs) that surround this region [86, 87]. The frequency
of H2 inversion differs between ethnic groups; the H2
haplotype is found primarily in Europeans and southwest
Asians. Notably, the presence of various homologous
LCRs in this short genomic region surrounding the MAPT
locus could trigger other genomic rearrangements, leading
Fig. 2 Organization of the rat, mouse and human Tau promoters. The lengths of the various regions of the promoter are not representative of
their precise localizations but are dependent on the cloning technique. Thus, differences in the length of a determined region among species are
not significant. Note the influence of allelic variants on promoter activity. CpG islands present in the promoter are indicated
Fig. 3 Transcription initiation sites (black perpendicular arrow) and termination sites (simple gray arrow). These sites enable the expression of the
complete Tau transcript/protein. For other sites, see Fig. 4b. Red numbers: initiation sites according to the database. Green numbers: initiation
sites described in [77]. FS: forward strand, RS: reverse strand
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to microdeletion/microduplication/microtriplication of
this short genomic region [29–32]. H2 inversion seems to
be a risk factor for genomic rearrangements such as
microdeletions [88].
The H1 haplotype is relatively heterogeneous com-
pared with H2. A total of 24 SNPs in the MAPT gene
vary in the H1 background haplotype and enable classifi-
cation of the gene into H1 sub-variants [89]. H1 haplo-
types or sub-haplotypes are associated with increased
risks of developing certain neurodegenerative diseases.
Although first established for PSP and CBD, the list of
pathologies is increasing and includes the following:
neurofibrillary tangle-predominant dementia, PD, AD, pri-
mary progressive aphasia, and argyrophilic grain disease
[72, 89–97]. However, Sobrido et al. have reported no as-
sociation between the H1 haplotype and FTD [98] and a
slight, but not significant, increase in the H2 haplotype
frequency has been reported in Pick disease [99].
Notably, DNA methylation is increased in the H1
haplotype compared with that in the H2 haplotype and
can be observed in both the blood and brain [82, 100].
Furthermore, differential methylation (hypomethylation
or hypermethylation, depending on the analyzed site)
could play a role in the association of the H1 haplotype
with the development of PSP, particularly for the methy-
lation sites within the 17q21.31 region where the MAPT
gene is located [100].
Functional effects of the H1 haplotype on pathology
The functional effects of the H1 haplotype on the devel-
opment of neurodegenerative diseases have been investi-
gated at different levels.
PSP and CBD, the first pathologies associated with the
H1 haplotype, display particular patterns of Tau isoform
expression. Indeed, Tau isoforms containing sequences
encoded by the alternative exon 10 of Tau mRNA are
preferentially found in degenerating neurons, suggestive
of altered Tau splicing. Consistent with these observa-
tions, the H1C sub-haplotype found predominantly in
these pathologies seems to favor exon 10 inclusion com-
pared with the H2 haplotype [101]. Caffrey et al. have
also reported an increase in exon 3 inclusion for the H2
haplotype [102]. Further, these authors have suggested
that the E3-encoded sequence could have a protective
effect against these pathologies, consistent with the ob-
served decrease in the fibrillar extension of Tau proteins
when the E3-encoded sequence is present [103].
Using luciferase assays, the H1 haplotype promoter has
been shown to be more efficient at promoting Tau tran-
scription compared with the H2 promoter [104–106];
however, these data are somewhat controversial because
allele-specific expression experiments have not detected a
difference in expression between these two haplotypes
[104–106]. Notably, using this method, the authors have
shown a decrease in H1 haplotype expression during aging.
Some polymorphisms have been demonstrated to
interfere with MAPT expression. Two allelic variants lo-
cated upstream of E0 (rs7210728) (±3000 nt) and down-
stream of E0 (rs242557) (±48000 nt) have been
identified as modulators of promoter activity according
to haplotype (H1 versus H2) [101, 106] (Fig. 2). Notably,
the second polymorphism, rs242557, is located only
approximately 6800 nt upstream of the second CpG27
island (Fig. 1, Fig. 2).
The relationship between MAPT haplotype and Tau
and/or α-synuclein pathologies has also been investigated
by studying brains affected by AD or α-synucleinopathies,
including PD and dementia with Lewy Bodies (LBs). Sur-
prisingly, the H1 haplotype may be protective against Tau
aggregation but favors α-synuclein aggregation in LBs
[107–109]. However, the results may be dependent on
the studied brain area, the pathology type, the aggre-
gate type and other factors associated with these path-
ologies, such as ApoE/α-synuclein haplotype and amyloid
aggregation. Thus, additional studies are needed to deter-
mine whether the MAPT haplotype has an effect on Tau
or α-synuclein deposition. Another method used to ascer-
tain the potential relationship between Tau haplotype and
tauopathy development involves examining the possible
relationships between MAPT haplotypes and biological
markers. A diagnostic test first developed for AD based on
three major biomarkers (amyloid peptide Aβ1-42, total
Tau (t-Tau) and Tau phosphorylated at Thr181 (p-Tau)) of
AD found in CSF has been proposed [110]. Unfortunately,
conflicting data have been obtained for the H1C sub-
haplotype regarding Tau levels in CSF [111, 112]. These
two groups have also reported correlations between spe-
cific MAPT SNPs and Tau levels in CSF. Among these
SNPs, at least some may be associated with an earlier stage
at onset [111]. More recently, an N-terminal fragment of
Tau has been identified in CSF as a new diagnostic marker
for various neurodegenerative diseases associated with
cognitive impairment [113]. If this result is confirmed,
then investigating the relationship between Tau haplotypes
and this new marker would be of interest.
Regulation of Tau RNA expression and splicing
Tau mRNA expression was initially identified in the brain
and, more precisely, in neurons by both northern blot and
in situ hybridization analyses; it has since been detected in
various tissues, including the cerebellum, kidney, muscle
and testis, using more sensitive methods such as RT-PCR,
microarray and RNA-Seq [57, 114–116]. However, al-
though Tau protein expression in peripheral tissues has
been clearly observed in rats [116], very little data con-
cerning such expression in human tissues have been
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reported [117], with the exception of reports of Tau
protein expression in pathological peripheral tissues
[37, 41, 118].
Mature Tau transcripts contain up to 16 exons [3, 57].
The different exons have been identified and numbered,
corresponding to their locations within RNA sequences
from different animal, primarily human, bovine and
murine, models. The first exon is generally named exon
0 (E0) in the literature, and exon 4A corresponds to the
alternative exon located between exons 4 and 5. The
exon numbers provided in the databases must be carefully
considered when determining the functions of analyzed
transcripts because different exons may be assigned the
same number depending on the transcript analyzed.
Three Tau transcripts of 2 kb, 6 kb, and 9 kb in
length are encoded by the MAPT gene (reviewed in
[57]). These transcripts differ from one another by
their splicing patterns, as demonstrated by the differ-
ences between the 6 and 9 kb transcripts [119], and
their polyadenylation sites (2 kb versus 6 kb) [120].
The abundance of data in databases largely confirms
the observed variations in splicing patterns and polya-
denylation sites but also suggests the existence of sev-
eral promoters, as detailed below.
5′ UTR/MAPT promoter
MAPT promoter identification in the E0 region
The MAPT promoter has been studied primarily in
three different models, namely human, rat and mouse
models. The MAPT promoter is characterized by a
high G + C content as well as by the absence of TATA
and CAAT boxes [65, 77, 121]. Several regions have
been determined to play important roles in Tau tran-
scription (Fig. 2).
First, the “core” promoter is located immediately up-
stream of the first exon (exon E0, previously named
exon −1) (Fig. 2) [64, 65, 77, 101, 121]. More detailed
studies of rat and mouse models have enabled differenti-
ation between the two sub-sequences in this core region
[121, 122] (Fig. 1). The sequence located 5′ of the core
sequence is involved in neuronal-specific expression in
rats and mice but not in humans, whereas expression of
the 3′ sequence is not tissue dependent [77, 121–123].
However, this apparent difference in the neuronal speci-
ficity of the core promoter between mice and humans
may be due to differences in the cell type and the length
of the promoter sequence used in constructs, as sug-
gested by Maloney and Lahiri [64]. These authors have
reported the influence of E0 on human promoter activity
and have identified a neuronal-specific sequence that in-
cludes the last 10 nt of E0 and the first 200 nt of the in-
tronic sequence located immediately downstream that
negatively regulates promoter activity (Fig. 2).
Other distal sequences (approximately −7000 to −1500 nt
upstream of exon E0) are involved in promoter activity
[64, 101, 121] (Fig. 2). The 3′ end of this sequence (approxi-
mately −3000 to 1500 nt) negatively regulates Tau expres-
sion in rats and humans [64–66, 101, 121]. The 5′ end of
this sequence (approximately −7000 to 3000 nt), which has
only been studied in mice, is also involved in promoter ac-
tivity [121]. In addition, a putative reverse sequence located
immediately downstream of E0 might be involved in
human MAPT regulation (Fig. 2) [64]. However, these
authors could not exclude interference from another
promoter because of identification of a hypothetical
gene, LOC100128977, immediately upstream of and in
the opposite orientation as the MAPT gene [124].
According to the technique used, several initiation
sites for Tau transcription have been reported in both
rats and humans [65, 77]. The human transcript se-
quences published in databases confirm the diversity of
the transcription start sites. However, some discrepan-
cies exist between the sites described in the literature
and those in databases. In particular, the initiation sites
of the published sequences are located in E0, whereas
the Ensembl database shows that various initiation sites
are present all along the gene in addition to those in E0
(Fig. 3, Fig. 4b) [125]. Three of these identified sites are
common between the literature and databases.
Trans factors
As demonstrated by electrophoretic mobility shift assay
(EMSA), the transcription factors SP1 and AP2 bind to the
Tau core promoter region and are necessary for promoter
activity [121, 122]. Another DNA sequence located between
the SP1 and AP2 sites influences promoter activity; how-
ever, the transcription factor involved remains to be identi-
fied [122]. EMSA has also revealed that SP1, progesterone
receptor (PR) and retinoic acid receptor (RAR) bind to the
human exon E0 sequence, although their functionalities re-
main to be demonstrated [64].
The human MAPT promoter region also contains puta-
tive binding sites for various other transcription factors,
such as Nrf1, MTF1, MBF1, MepI, and GCF [64, 101].
Some of these sites are shared between the H1 and H2 hap-
lotypes, such as the AP2 and SP1 sites mentioned above.
Interestingly, among these common sites, four sites corre-
sponding to an Aβ-interacting domain have also been iden-
tified in the distal region of the Tau promoter [64, 126]. Aβ
is a pathological peptide generated via deregulated prote-
olysis of amyloid precursor protein (APP). This peptide ag-
gregates during AD and leads to the observed pathology of
this disease according to the amyloid cascade hypothesis.
This aggregation/accumulation of Aβ is not a feature com-
mon to all tauopathies, but it does occur in some, such as
AD and Down syndrome. Several studies have suggested
that the pathological effect of Aβ is mediated by Tau
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(reviewed in [127, 128]). Thus, determining whether the
Aβ-interacting domain actually regulates Tau expression
directly and thus participates in the development of Tau
pathologies in which both amyloid and Tau aggregates are
present would be of interest.
Does MAPT have only one promoter?
Alternative initiation transcripts largely contribute to
transcriptome and proteome diversity, and more than
40 % of genes have at least two promoters, as demon-
strated in flies (reviewed in [129, 130]). Although the re-
gion around E0 contains the only promoter for MAPT
that has been described in the literature, Andreadis [57]
hypothesized the existence of additional Tau promoters
to explain variations observed in neuronal specificity
and NGF susceptibility of Tau expression according to
the different Tau transcripts [77, 119, 131]. Currently,
new data are available in databases that reinforce this
hypothesis; at least 6 other exons distal to E0 have been
identified as the first exons of various transcripts.
One of the potential additional promoters may be as-
sociated with the initiation of transcription at exon E1.
Indeed, considering the number of identified tran-
scripts, E1 is the most frequent exon where transcrip-
tion is initiated after E0 (transcripts initiated at E0: 9
and E1: 5) for the H1 haplotype, further suggesting the
possible existence of an unidentified promoter. E1 is
located 68000 nt distal to E0. Similar to E0 [57], se-
quence analysis has revealed no TATA or CAAT con-
sensus binding sites in E1; however, a GC box specific
for SP family members is present near this exon [132].
Indeed, one potential SP1 site and five sites for AP-2α
binding have been identified 200 nt upstream of E1
using the ALGGEN server [133]. The absence of E0
would result in a change in the 5′ UTR length but
would not alter the coding sequence because E0 is a
non-coding exon, while E1 is a partially coding exon
(Fig. 1). On the reverse strand (H2 haplotype), tran-
scripts listed in the Ensembl database begin primarily
with E1 [125] (Fig. 3).
The other initiating exons near the E2, E3, E4A and E5
regions are located more than 10,000 nt and up to
25,000 nt distal to E1, suggesting that more than one alter-
native promoter may exist. Interestingly, the CpG21 island
is located immediately upstream of E4A at the beginning of
the short transcript MAP-010/ENST00000576238, as de-
scribed above in the CpG island section (Fig. 4b).
Tau splicing
Here, we will not describe the splicing mechanisms in detail
because they have been discussed in previous reviews; how-
ever, we will focus on the Tau splicing pattern because
splicing is an indirect mechanism of protein function
modulation via sequence modification [24, 57, 61, 134].
Published data
Tau alternative splicing is dependent on the develop-
mental stage, tissue and species.
Central nervous system (CNS) The following are gen-
erally recognized facts regarding Tau splicing in the
human CNS.
Fig. 4 Splicing patterns of human Tau transcripts. a Classical splicing pattern described in the literature. The insertion of exons 4A and 6 rarely
occurs in the brain (shaded in pale orange) and varies according to which 3’ splice site is used. E8 insertion (shaded in dark orange) has not been
reported in humans but has been described in different animal models and in the human Ensembl database. b Hypothetical splicing according
to the Ensembl database. The MAPT numbers correspond to those in the Ensembl database. White, non-coding regions; gray, constitutive coding
exons. Yellow, orange, pink, green, purple and blue represent the alternative exons 2, 3, 4A, 6, 8 and 10, respectively
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(i) In the fetal brain, only one isoform is predominantly
expressed, with insertion of the constitutive coding
exons (E1, E4, E5, E7, E9, E11, E12, and E13/14).
E1 is considered a coding exon because it contains
the initiating ATG codon. In addition, there are no
reports in the literature suggesting the presence of
non-coding E0 during the fetal stage [3, 57, 135, 136].
(ii)E2, E3 and E10 are specific to the adult brain (Fig. 4a).
Consistent with this statement, 6 protein isoforms have
been identified in the human adult brain that contain
sequences encoded by exon 2, exon 3 and/or exon 10.
Generally, these 6 isoforms are named 2N3R, 1N3R,
0N3R, 2N4R, 1N4R, and 0N4R. The designations 0 N,
1 N and 2 N indicate the exclusion of E2 and E3, the
inclusion of E2 and the inclusion of both E2 and E3,
respectively. Notably, the insertion of E3 is dependent
on the presence of E2, which corresponds with an
atypical feature of the splicing event. Globally, E3
inclusion can be considered a rare event compared
with E2 insertion or complete Tau transcription, as
evidenced by RT-PCR [114, 137]. Conversely, 3R
and 4R indicate the exclusion and inclusion of E10
[115, 138], respectively, which has been previously
reviewed [3, 139].
Peripheral tissues Considering peripheral tissues, in-
cluding the peripheral nervous system (PNS), the alter-
native exons described above are often included with
other exons that are nearly absent in the CNS. Indeed,
exon 4A (E4A) is present specifically in the PNS and ret-
ina, and exon 6 (E6) is found in the spinal cord and skel-
etal muscle. Interestingly, the lengths of these latter two
exons, E4A and E6, are modulated by the choice of 3′
splice site. Indeed, two possible 3′ splice sites exist for
E4A (E4A, E4ALong), and there are 3 splice sites for E6
(E6c, E6p, E6d) [41, 117, 137] (Fig. 4a). However, al-
though isoforms containing E4ALong, E6p, and/or E6d
have been reported in the literature, they are not present
in human databases (Ensembl, UCSC). These observa-
tions bring into question the frequencies at which these
different 3′ splice sites are used. Considering the pos-
sible co-insertion of alternative exons, in ENSEMBL/
UCSC sequences, E4A is always inserted when E6 or
E6 and E8 are included with E2, E3 and E10. However,
an E4A-containing isoform without E6 but containing
E2, E3 and E10 has been cloned [140]. Furthermore, in
Ensembl database, the isoforms containing exon 6c also
contain exons 2, 3, 4A and 10 with or without exon 8,
although studies by Andreadis’s group have demon-
strated that all combinations of E6c, E6p, and E6d with
the other alternative exons are possible [141]. The in-
clusion of E6p and E6d results in the translation of a
truncated protein that lacks microtubule-binding sites be-
cause of a change in the reading frame that introduces a
stop codon. Tau proteins containing E6c- or E6d-encoded
sequences have been identified in several tissues, in-
cluding brain and muscle tissues, using specific anti-
bodies [142, 143]. These new forms, although minor,
could interfere with the role of Tau in axonal transport
[144, 145]. Note also the rare but possible inclusion of
E6 in the fetal brain [57].
Suggestions from databases
Recent data from databases suggest that the splicing
pattern of MAPT may be more complicated than sug-
gested by the primary characteristics described above, al-
though particular splicing events are most likely rare.
Although the majority of transcripts described in data-
bases are coding transcripts, some are not (Fig. 4b).
Non-coding transcripts have been identified that cor-
respond primarily to isoforms with the deletion of at
least one constitutive exon. One such non-coding tran-
script (MAPT-011 ENST00000571311) (Fig. 4b) may be
processed by NMD. Notably, none of these variants
have been described in the literature, although they are
listed in Ensembl. Their existence and potential roles
(perhaps as lncRNAs) remain to be investigated and
confirmed.
Splicing and H1/H2 haplotypes A comparison of the
transcripts from the forward (H1) and reverse (H2)
strands that have been published in databases such as
Ensembl has revealed that the haplotype might affect
some splicing events. This situation has already been re-
ported for E10 (see the sub-chapter “Functional conse-
quence of H1 haplotype on pathology”).
Alternative 5′ UTR/alternative first exon In the litera-
ture, E0 is always described as the first exon in all
MAPT transcripts. However, when analyzing different
MAPT transcripts in databases such as Ensembl, it is ap-
parent that E0 can be present or absent in the H1 haplo-
type; thus, it may be considered an alternative exon due
to alternative promoter usage. Furthermore, E0 inclusion
is less frequent in the sequences of transcripts from the
reverse strand (H2 haplotype) (Fig. 3). Several possible
initiating transcription sites may exist in E0 as described
above (see the sub-chapter regarding promoters), leading
to different possible lengths of E0 and of the 5′ UTR be-
cause E0 is a non-coding exon (Fig. 3). According to the
Ensembl database, the length of E1 may also vary de-
pending on the first exon that is included (E0/E1). In-
deed, E1, a partially coding exon, is 150 or 133 nt long
when initiated from E0 or E1, respectively, on the for-
ward strand. For H2 (the reverse strand), in the absence
of E0, the length of E1 is three nucleotides longer at its
5′ side (153 nt) or 17 nucleotides shorter at the ATG
codon (133 nt). These variations in E1 length do not
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affect the sequence of the translated protein because the
5′ end is non-coding; therefore, this length variation
only results in modification of the 5′ UTR of the tran-
script (Fig. 2).
Additional exons The possible insertion of additional
exons, although not yet identified in the published hu-
man transcripts, is suggested by data in the Ensembl
database. This possibility is the case for E8, which was
first identified in bovines and then in certain species
such as rhesus monkeys [146, 147] but has not been de-
scribed in humans [148] (Fig. 4a). However, according to
the Ensembl database, transcripts containing E8 include
all of the alternative exons except for E0, which can be
included or excluded (MAPT-203 ENST00000344290,
MAPT-004 ENST00000415613). Studies of different
animal species have shown that E8 insertion is possible
in the absence of certain alternative exons. In particu-
lar, 4 transcripts containing E8 have been identified in
cows [148]. All of these transcripts also contain E2 and
E10 but lack E4A. These transcripts differ from each other
by the presence or absence of E3 or E14. In mice, only one
transcript (MAPT-006/ENSMUST00000106993) has been
identified with E8, and this transcript contains E10 as the
only other alternatively spliced exon.
New exons that have never been reported in the lit-
erature are present in certain transcripts. The insertion
of most of these new exons results in truncated tran-
scripts at the 5′ and/or 3′ ends of Tau mRNA (Fig. 4b).
For example, the exon located between E1 and E2, named
E1A, is present in the only transcript that potentially
undergoes NMD (MAPT-011, ENST00000571311/ENST0
0000625688) (Fig. 4b). In addition, we identified exon
E4B, which is positioned between E4A and E5 and is
spliced to E5, producing a non-coding but processed
transcript composed of two exons (MAPT-012,
ENST00000577017/ENST00000627800) (Fig. 4b).
Other exons generated by the extension of known exons
have been found in particular isoforms in Ensembl data-
base. Exon E4ALong has been described in MAPT tran-
scripts as another spliced form of exon 4A [41] (see
above). E4ALong may also be the only exon in a short
transcript listed in Ensembl database (MAPT-010 ENST00
000576238/ENST00000625417) (Fig. 4b). Another ex-
ample is extended E3 (E3Ext, 5658 nt versus E3, 87 nt),
which may be the first exon in the MAPT-009 transcript
(ENST00000576518/ENST00000626880) (Fig. 4b). Exon
E3Ext is composed of exons E3 and E4, the 1603 nt up-
stream of E3 and the entire retained intron between E3
and E4 (3903 nt) (Fig. 4b). E3Ext may be a partially coding
exon because an ATG is located 100 nt before E4 and is
spliced to exon 5, encoding a protein that lacks part of the
5′ region that contains the acidic projection domain
(Fig. 4b). Because the alternative exons E4A, E6, and E10
are excluded from this transcript, it may be translated
more precisely in this shortened form during fetal devel-
opment. Interestingly, if this transcript exists, then it
has a short 3′ UTR. Another example of an extended
exon is extended exon E4 (E4Ext), which corresponds to
exon E4 in-frame with partial intronic sequences (2883 nt
upstream and 2066 nt downstream) and which may be the
only exon in the non-coding transcript MAPT-014
(ENST00000572440/ENST00000628437) (Fig. 4b). Cer-
tainly, the existence of these two latter transcripts must be
confirmed under physiological conditions.
Splicing and pathology
Defects in splicing can be pathological events that lead to
or have roles in tauopathy-type neurodegenerative pro-
cesses. Indeed, missplicing has been clearly associated with
certain familial tauopathies, such as FTDP-17 and DM
(reviewed in [24, 134]). These pathologies have been asso-
ciated with either mutations in MAPT cis-elements
(FTDP-17) (review in [61]) or with microsatellite expan-
sion in the non-coding regions of various genes, leading
to variations in the expression of splicing factors belong-
ing to the CELF and MBNL families (DM, reviewed in
[24]). Notably, numerous mutations in MAPT are located
in or near E10 (upstream and downstream), favoring E10
inclusion either by destabilizing a stem–loop structure
that encourages access to the 5′ splice site or by modifying
splicing factor or U1/E6 snRNP binding sites (reviewed in
[61]). For sporadic tauopathies, the MAPT haplotype may
influence splicing, as described above. Moderate Tau mis-
splicing events have also been observed in numerous
other tauopathies, such as AD (reviewed in [24]). In AD
and PSP, modified miRNA expression may result in alter-
ations in the expression of certain splicing regulatory fac-
tors, which would then influence Tau splicing [149, 150].
As such, the splicing pattern of MAPT transcripts could
be determinant in tauopathy-type neurodegenerative pro-
cesses. Consistent with this hypothesis, none of the mouse
transgenic models have reproduced Tau pathology in the
absence of a Tau mutation in the coding region. However,
Tau pathology has been observed in mouse models when
the human Tau gene is expressed in the absence of en-
dogenous MAPT expression. These observations suggest
that the correct ratio between the differentially expressed
isoforms is determinant in the tauopathy process in the
absence of Tau coding mutations. Thus, the difficulty in
obtaining animal models that reproduce tauopathies in
the absence of a Tau mutation most likely results from the
MAPT splicing pattern, which differs among animal spe-
cies [151–155]. For example, exon 10 inclusion is highly
increased in mouse and rat brains, whereas exon 2 inclu-
sion is observed less frequently in mice compared with
humans. Similarly, differences in the 3′ ends of the tran-
scripts, as described below (section 3.3), may stem from
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splicing differences that potentially interfere with the
human specificity of the tauopathy process. However, the
contribution of other undetermined factors cannot be
excluded at this point.
3′ UTR/alternative termination sites: Roles of RNA stability
and localization
The 2 and 6 kb forms of mature Tau RNA are generated
from different 3′ UTRs. Indeed, two alternative polyade-
nylation sites followed by a short poly(A) sequence
located at a distance of approximately 4000 nt have been
found in different animal species [74, 115, 120, 156]
(Fig. 3). Thus, at least two transcription termination sites
could be used, resulting in transcripts with short or long
3′ UTRs. Interestingly, the first polyadenylation site is
located within an intronic sequence that is deleted in
some transcripts from various animal species. Indeed, in
some Ensemble database transcripts from mouse, rat
and cow, E14 is separated from E13 by a short intronic
sequence of approximately 900 nt [148, 157]. The
splicing of E13 to E14 results in extension of the
C-terminus of the protein and truncation of the 3′ UTR.
In humans, the short intronic region between E13 and
E14 is always retained, as described in the literature [74]
and databases such as Ensembl. Thus, the splicing of
E13/E14 may be a feature that differs between animals
and humans.
The 3′ UTR may contain cis-elements that decrease
Tau RNA expression. Indeed, binding sites for miR-34a
and miR-34c-5p have been reported that lead to de-
creased Tau RNA and protein expression [45, 156].
Interestingly, increased Tau expression and decreased
miR-34C-5p expression have been correlated with the
chemoresistance of gastric cancer to paclitaxel [45]. Re-
cent studies have demonstrated a role of miR-485-5p in
axonal development and Tau expression downregulation
during synaptic plasticity in hippocampal rat neurons.
The Tau 3′ UTR sequence has two possible miR-485-5p
binding sites [158] and contains a target sequence for
miR-132-3p, which is strongly downregulated in the
brains of AD patients [149]. However, a mutation in the
binding site does not completely abolish miR-132 activ-
ity, suggesting that other indirect mechanisms exist by
which miR-132 affects Tau expression.
In rat transcripts, a 240-nt region in the 3′ UTR has
been implicated in RNA stability and axonal localization
[159–161]. Several proteins, such as HuD (an Elav pro-
tein family member), insulin-like growth factor mRNA-
binding protein IMP-1, Ras-regulatory protein G3BP,
interleukin enhancer binding factor 3 (Ilf3) and NF90,
bind to this sequence and are potentially involved in the
axonal localization of these transcripts [162]. Unfortu-
nately, no such data are available in humans, and these
data must be generated to determine whether similar
mechanisms protect human RNA and guide transcripts
to their proper locations.
Conclusion: The hidden facets of Tau gene
expression
The aim of this review was to highlight the different steps
of MAPT gene expression regulation at the DNA and RNA
levels. We focused on the following three aspects of the in-
fluence of DNA sequence on MAPT expression: repeated
sequences, CpG islands and haplotypes. Notably, scarce
data concerning repeated sequences have been reported in
the literature, whereas CpG islands and haplotypes are be-
ginning to be well documented. Functional interest in re-
peated sequences has recently been described in the
literature for other genes. For MAPT, the report of the role
of SSR58 in E10 insertion confirms the interest in such
studies [73]. Concerning the regulation of RNA expression,
we focused on the potential roles of UTR sequences and al-
ternatively spliced isoforms. Additional data are necessary
to confirm or exclude the possible existence of another pro-
moter. Furthermore, differences exist between isoforms re-
ported in the literature and those reported in databases,
suggesting that some splicing possibilities remain to be ex-
plored. Data regarding Tau isoforms reported in the litera-
ture primarily concern the nervous system. However, Tau
(transcripts/proteins) is expressed in other tissues, and its
expression may play roles in some pathologies, such as can-
cer and IBM. Thus, increasing our understanding of the
isoforms expressed in these different tissues and of the
regulation of their expression, which may differ from those
in the brain (for example, different promoters and polyade-
nylation sites) is of interest. In addition to the isoforms de-
scribed in the literature, the data from databases suggest
the possible existence of shortened Tau isoforms, non-
coding transcripts and one transcript that may undergo
NMD, thereby bringing into question the roles of these
hypothetical forms. Finally, the Tau sequences present in
databases also suggest the possible existence of a long non-
coding MAPT RNA and 3 MAPT anti-sense isoforms; how-
ever, these sequences have not yet been reported in the lit-
erature. Therefore, they were not discussed here because of
the lack of information. Knowledge of these particular Tau
transcripts will most likely increase our understanding of
Tau expression regulation.
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